SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC

Inclusion Criteria: * Histologic or cytologic diagnosis of SCLC * limited-stage disease is defined as disease confined to the ipsilateral hemithorax, which can be safely encompassed within a radiation field * No prior chemotherapy, or radiotherapy * Performance status of 0, 1, 2 on the ECOG criteria. * At least one unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST. 2000). * Adequate hematologic (neutrophil count \>= 1,500/uL, platelets \>= 100,000/uL), hepatic (transaminase =\< upper normal limit(UNL)x2.5, bilirubin level =\< UNLx1.5), and renal (creatinine =\< UNL) function * If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device \[IUD\], birth control pills, or barrier device) during and for 3 months after trial. If male, use of an approved contraceptive method during the study and 3 months afterwards. Females with childbearing potential must have a urine negative HCG test within 7 days prior to the study enrollment. Exclusion Criteria: * Non small cell lung cancer and carcinoid * Supraclavicular lymphadenopathy * Inability to comply with protocol or study procedures. * Moderate and severe ventilation dysfunction * Medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease * Second primary malignancy that is clinically detectable at the time of consideration for study enrollment. * Pregnant or breast-feeding. * Enrollment in other study within 30 days